Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV
Lena van der Wekken‐Pas, Fabian Weiß, Charlotte Simon-Zuber, Rena Sebisch, Carmen Wiese, Elisabeth van Leeuwen, David Burger, Angela Colbers
Abstract
This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.
Topics & Concepts
RilpivirineMedicineHuman immunodeficiency virus (HIV)VirologyInternal medicineAntiretroviral therapyViral loadHIV/AIDS Research and InterventionsHIV Research and TreatmentHIV/AIDS drug development and treatment